After pulling Blenrep from US markets, GSK plots a comeback with PhIII multiple myeloma trial success
GSK announced Monday that its multiple myeloma drug Blenrep succeeded in a Phase III trial as part of a second-line combination treatment for patients whose …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.